Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer

Inclusion Criteria: * Patients must have histologically confirmed advanced, refractory gynecologic cancer. * Patients must have received prior chemotherapy, and must have residual or recurrent disease after initial therapy or after subsequent therapy. * Patients must have at least one site of bi-dimensional measurable disease as defined in section 9 or must have evaluable but radiographically non-measurable disease associated with CA-125 \> 50 units/ml on two measurements at least one week apart. Baseline measurements and CA-125 must be obtained for all patients within four weeks before registration. * Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0-1. * Patients must not have received any hormonal or immunologic therapy for 2 weeks or cytotoxic chemotherapy or radiation therapy for 4 weeks (nitrosoureas and mitomycin C require 6 weeks) prior to registration. * Patients may not have a history of prior malignancy in the past 5 years other than non-melanoma skin cancer or in situ carcinoma of the cervix. * Patients must have documented adequate organ function within 4 weeks of registration defined as: * Marrow: WBC ≥ 3000/mm3, ANC ≥ 1500/mm3 , Hgb ≥ 8.0 g/dl, platelets ≥ 100,000/mm3 * Hepatic: Total Bilirubin ≤ ULN, SGOT or SGPT and Alkaline Phosphatase must be within the range allowing for eligibility, as in the table below * SGOT or SGPT: Meets 1 of the following criteria: * Alkaline phosphatase (AP) normal AND SGOT or SGPT norma…